-
Wall Street Reacts To Celgene's Reported Interest In Juno
Wednesday, January 17, 2018 - 3:39pm | 521Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...
-
Early Keytruda Results Win Merck An Upgrade
Tuesday, January 16, 2018 - 1:19pm | 345Read More...Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing...
-
Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts?
Monday, November 13, 2017 - 11:23am | 401Read More...Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...
-
Gilead Gets An Upgrade Amid 'Game-Changing' Kite Deal
Thursday, August 31, 2017 - 8:48am | 487Read More...It’s taking time, but three days after Gilead Sciences, Inc. (NASDAQ: GILD) announced its acquisition of Kite Pharma Inc (NASDAQ: KITE), the Street seems to be deciding it’s a good thing. Gilead’s stock traded up a modest 2.5 percent and three analysts reiterated Hold ratings...
-
ZIOPHARM Announces Clinical Data On Brain Cancer Drug
Thursday, November 17, 2016 - 10:01am | 319Read More...ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is a biopharmaceutical company dedicated towards developing a portfolio of cancer therapies through synthetic immuno-oncology. Ziopharm announced Thursday an update related to an ongoing trial of its AD-RTS-hil-12 + orally-administered veledimex that's...
-
Exclusive: Oasmia Chairman Talks About How They're Changing Cancer Drug Delivery Treatment
Friday, August 26, 2016 - 2:25pm | 504Read More...Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM) is one of only three Swedish companies listed in the United States. While well known in Sweden, Oasmia entered the U.S. market in 2015 and is making waves in the world of oncology with a new drug delivery system that aims to...
-
Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
Tuesday, August 9, 2016 - 7:33am | 255Read More...Bristol-Myers Squibb Co (NYSE: BMY) saw its shares crater from near $75 last week to nearly $60 per share after the company reported a major setback for its cancer-treating drug, Opdivo. Bristol-Myers said Opdivo failed to meet a primary endpoint in the treatment of lung cancer during the...
-
Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price
Tuesday, March 29, 2016 - 9:18am | 189Read More...Shares of Medivation Inc (NASDAQ: MDVN) were trading lower by more than 6 percent heading into Tuesday's market open as the company's drug pricing have come under scrutiny by the U.S. Congress. According to ABC News, a group of U.S. lawmakers initiated a campaign to potentially lower the price of...
-
Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%
Thursday, January 28, 2016 - 11:46am | 152Read More...Shares of Incyte Corporation (NASDAQ: INCY) fell more than 10 percent on Thursday after the company said it will stop an ongoing Phase 2 sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP. According to Incyte's press release, the company...
-
OncoMed Pharma Crashes 40% After Poor Trial Data
Monday, January 25, 2016 - 9:19am | 254Read More...Shares of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) plunged 42 percent during Monday's pre-market session after the company provided an update on its Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data...
-
Here's Why Shares Of Onco Genex Pharma Are Plunging
Thursday, January 21, 2016 - 9:28am | 172Read More...Shares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI), a nano-cap and clinical-stage biopharmaceutical company, were trading lower by nearly 25 percent at $0.580 early Thursday morning. OncoGenex Pharmaceuticals announced after Wednesday's market close that data from its Phase 2 Spruce trial which...
-
Juno Therapeutics Lower, To Acquire AbVitro For $78 Million In Cash And Nearly 1.30 Million Shares
Monday, January 11, 2016 - 1:35pm | 295Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) were trading lower by more than 4 percent at $34.78 during Monday's trading session. Juno Therapeutics announced earlier that it has acquired AbVitro, Inc., a private biotechnology company whose technology platform accelerates the development...
-
Vetr Crowd No Longer Uber-Bearish On Puma Biotech
Friday, December 11, 2015 - 1:16pm | 352Read More...Shares of Puma Biotechnology Inc (NYSE: PBYI) plunged nearly 20 percent on Friday. The Vetr crowd upgraded its rating on Puma Biotech to two stars out of a possible five from a prior one-star rating. The Vetr crowd's less-bearish rating is accompanied by its crowd-sourced price target...
-
Market Wrap For January 27: China Concerns, Declining Home Sales, Tomorrow's Fed Meeting and Obama's Speech Keep Markets Lower
Monday, January 27, 2014 - 4:48pm | 2489Read More...U.S. stocks picked up where they left off on Friday and declined today as investors have plenty on their mind. With earnings being a mixed bag, investors are looking at emerging markets and economic data to support a bullish case for equities. On the emerging market front, investors remain...
